ArticleTheranostics2018
Acid-degradable Dextran as an Image Guided siRNA Carrier for COX-2 Downregulation.
Article in Theranostics, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 34 citations in OpenAlex.
- PSMA-specific degradable dextran for multiplexed immunotargeted siRNA therapeutics against prostate cancer.Nanoscale · 2022Article
- Theranostic small interfering RNA nanoparticles in cancer precision nanomedicine.Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology · 2020Review
- Cellular Delivery of Bioorthogonal Pretargeting Therapeutics in PSMA-Positive Prostate Cancer.Molecular pharmaceutics · 2020Article
- PD-L1 siRNA Theranostics With a Dextran Nanoparticle Highlights the Importance of Nanoparticle Delivery for Effective Tumor PD-L1 Downregulation.Frontiers in oncology · 2020Article
- Detection of tyrosine kinase inhibitors-induced COX-2 expression in bladder cancer by fluorocoxib A.Oncotarget · 2019Article
- Theranostics and metabolotheranostics for precision medicine in oncology.Journal of magnetic resonance (San Diego, Calif. : 1997) · 2018Review
- Endogenous pH-responsive nanoparticles with programmable size changes for targeted tumor therapy and imaging applications.Theranostics · 2018Review
- A nanomedicine approach enables co-delivery of cyclosporin A and gefitinib to potentiate the therapeutic efficacy in drug-resistant lung cancer.Signal transduction and targeted therapyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.